FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPR	OVAL					
OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					
	OMB Number: Estimated average bur					

					Or	Section	on 30(n)	or tne	Investment	Con	npany Act	OT 1940							
1. Name and Address of Reporting Person* Werth Peter J.					2. Issuer Name and Ticker or Trading Symbol Cingulate Inc. [CING]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last)		irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/25/2024						X		(give title	Λ	Other (s			
1901 W. 47TH PLACE					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) KANSA	S CITY K	S	66205											X		iled by Mor		orting Perso n One Repo	
(City)	(S	tate)	(Zip)		Ru	ıle	10b5-	1(c) Transa	acti	on Inc	lication							
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - Non	-Deriv	ative	Se	curities	s Ac	quired, E	Disp	osed o	of, or Be	neficia	lly	Owned	t			
1. Title of Security (Instr. 3) 2. Trans: Date (Month/I					Execution Date,			Code (Instr. 5)			ed (A) or str. 3, 4 ar	or 5. Amount of Securities Beneficially Owned Following Reported		es ally Following	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	(A) or (D) Price			orted saction(s) tr. 3 and 4)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				ransaction of ode (Instr. Derivative			Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Pre- Funded Warrant (right to buy)	\$0.0001	03/25/2024			J (1)		7,053		03/25/2024		(2)	Common Stock	7,053		(1)	694,09	6	I	By Werth Family Investment Associates LLC ⁽³⁾
	A - -																		

1. Name and Address of Reporting Person* Werth Peter J.									
(Last)	Last) (First) (Middle								
1901 W. 47TH PL	ACE								
(Street)									
KANSAS CITY	KS	66205							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person* Werth Family Investment Associates LLC									
(Last)	(First)	(Middle)							
C/O CINGULATE INC.									
1901 W. 47TH PLACE									
(Street)									
KANSAS CITY	KS	66205							
(City)	(State)	(Zip)							

Explanation of Responses:

^{1.} On January 25, 2024, the Issuer and Cingulate Therapeutics LLC ("CTx"), a wholly-owned subsidiary of the Issuer, entered into a Note Conversion Agreement with Werth Family Investment Associates LLC ("WFIA"), pursuant to which WFIA agreed to convert the remaining principal amount plus all accrued interest thereon (other than the Outstanding Interest (as defined below)), or \$3,287,500, under the Amended and Restated Promissory Note, dated May 9, 2023 (the "Note"), that CTx issued to WFIA into pre-funded warrants to purchase 687,043 shares of common stock of the Issuer, at a conversion price per pre-funded warrant of \$4.785. Due to a calculation error, \$33,750 of interest (the "Outstanding Interest") on the remaining principal amount of the Note remained as of January 25, 2024. The Outstanding Interest was converted into additional pre-funded warrants to purchase 7,053 shares of common stock of the Issuer at a conversion price per pre-funded warrant of \$4.785.

^{2.} The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of common stock of the Issuer.

3. Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

/s/ Shane J. Schaffer, Attorney-03/27/2024

in-Fact Peter J. Werth

/s/ Shane J. Schaffer, Attorney-

in-Fact Peter J. Werth, for Werth Family Investment

03/27/2024

Associates LLC

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.